Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 107 participants.
Also called NCT01617655
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 107 participants
- Sponsor
- Registry
-
NCT01617655 -
2012-001096-37
-
- Other papers using this trial's data
- Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada, Netherlands, Russia, South Africa
- Registry status
- Completed
Technical summary
Registry record NCT01617655. Randomized; quadruple masking; primary purpose treatment. Start 2012-06 (registry gives no type); primary completion 2014-05 (actual). Results posted on 2015-11-06.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH)
- Condition
- Hypercholesterolaemia
- Intervention (Drug)
- Alirocumab
- Intervention (Drug)
- Placebo (for alirocumab)
- Intervention (Drug)
- Lipid Modifying Therapy (LMT)
- Lead sponsor
- Sanofi
- Collaborator
- Regeneron Pharmaceuticals
Record details
- Record id
cardio:ct-nct01617655- Content hash
5c13e5c5df173139617c55e544c577f3012e31d6bb309e1f145dd9eb29f59d76